Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Caucasian male or female out-patients;~* aged 18 to 75 years inclusive;~* diagnosis of probable or definite amyotrophic lateral sclerosis according to the El Escorial revised criteria (1);~* first symptoms of ALS by no more than 1.5 years;~* in treatment with steady regimen of riluzole for a minimum of 3 months before study entry, and desiring its continuation;~* FVC ≥ 75% of predicted;~* no conditions known to be contraindications to the use of TUDCA;~* written informed consent.~Exclusion Criteria:~* subjects who underwent tracheostomy;~* subjects who underwent resection of gall bladder;~* subjects with signs of conduction blocks of motor nerves, sensory nerves or both on nerve conduction study;~* subjects with clinical signs of dementia;~* subjects with active peptic ulcer;~* subjects with active malignancy;~* subjects with bulbar onset;~* female subjects who are pregnant or lactating~* subjects who have received an experimental drug or have participated in a clinical trial within 3 months prior to screening~* employees of the investigator or study centre with direct involvement in the proposed study or other studies under the direction of that investigator or study centre.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TUDCA (Type: EXPERIMENTAL): tauroursodeoxycholic acid di-hydrate
- placebo (Type: PLACEBO_COMPARATOR): excipient lactose

Based on this trial design, predict the completion outcome and termination type (if applicable).